Children鈥檚 National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases

March 10, 2021

The following is an excerpt from a press release from Takeda. Read the press release in its entirety here. Children鈥檚 National Hospital and Takeda Pharmaceutical Company Limited announce the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help […]

Baxject II Device Currently Out of Stock

January 13, 2021

HFA has received the following information from Takeda regarding the Baxject II Device: The Baxject II device, that comes in a 5 unit blister pack and may be ordered separately from Takeda products, is currently out of stock due to circumstances that are not safety related. This does not impact BaxJect II devices that are […]

Takeda Suspends Screening & Further Enrollment in TAK-754, TAK-748 Clinical Studies

August 21, 2020

The following is an excerpt from an update from Takeda. Read the update in its entirety here. Takeda recently informed HFA of it’s decision聽to suspend screening and further enrollment in聽the TAK-754 and TAK-748 clinical studies, effective immediately. TAK-754 is an AAV8 gene therapy for the treatment of hemophilia A currently in Phase 1/2 clinical聽development, while […]

Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis聽

April 27, 2020

Below is a letter from Takeda. “To our valued patients, customers and other stakeholders,聽 As the COVID-19 crisis continues to unfold, Takeda鈥檚 Patient Assistance Response team is working around the clock to help ensure that the people who need our medicines and treatments can continue to access them safely and without interruption.聽 Consistent with our […]

Takeda Announces Program Updates During COVID-19

March 31, 2020

The following is information shared with the bleeding disorders community by Takeda. “Takeda has been closely monitoring the news surrounding COVID-19. Our highest priority is the health and safety of our community during this uncertain time. We are taking steps to help ensure the community鈥檚 safety including postponing upcoming educational events such as our HELLO […]

Takeda Guidance on Novel Coronavirus and Product Supply

March 20, 2020

The following is a letter from Takeda. 聽“To the bleeding disorders community,聽 As a global pharmaceutical leader, our top priority during the ongoing COVID-19 outbreak is to do all we can to make sure our medicines and services continue to reach the individuals who rely on them, while we protect the health of our employees, […]

VONVENDI Recall 鈥 Takeda Response

March 6, 2020

As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U. vials on Feb. 25, 2020. HFA and NHF recognize that recalls can be very unsettling for many in the bleeding disorders community. On Feb. 27, 2020, the patient organizations announced聽they had submitted a […]


February 27, 2020

Takeda announced the recall of two lots of VONVENDI vonWillebrand factor (recombinant) 1,300 I.U. vials on February 25, 2020. HFA and NHF recognize that recalls can be very unsettling for many in the bleeding disorders community. We are in communications with Takeda to obtain additional detailed and timely information regarding the events that led up […]

Takeda Completes Acquisition of Shire, Becoming a Global, Values-based, Biopharmaceutical Leader

January 23, 2019

The following is a press release from Takeda, formerly Shire. Find the original press release here. Takeda Pharmaceutical Company Limited announced the completion of its acquisition of Shire, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.